Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy

Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed clinical outcomes for patients infused with standard-of-care...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferreri, Christopher J., Hildebrandt, Michelle A. T., Hashmi, Hamza, Shune, Leyla O., McGuirk, Joseph P., Sborov, Douglas W., Wagner, Charlotte B., Kocoglu, M. Hakan, Rapoport, Aaron, Atrash, Shebli, Voorhees, Peter M., Khouri, Jack, Dima, Danai, Afrough, Aimaz, Kaur, Gurbakhash, Anderson, Larry D., Simmons, Gary, Davis, James A., Kalariya, Nilesh, Peres, Lauren C., Lin, Yi, Janakiram, Murali, Nadeem, Omar, Alsina, Melissa, Locke, Frederick L., Sidana, Surbhi, Hansen, Doris K., Patel, Krina K., Castaneda Puglianini, Omar Alexis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412575/
https://www.ncbi.nlm.nih.gov/pubmed/37558706
http://dx.doi.org/10.1038/s41408-023-00886-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412575/
https://www.ncbi.nlm.nih.gov/pubmed/37558706
http://dx.doi.org/10.1038/s41408-023-00886-8

Ejemplares similares